BridgeMD
New treatment option for Prostate Cancer
Official title Can MRI of the Prostate Combined With a Radiomics Evaluation Determine the Invasive Capacity of a Tumour
ClinicalTrials.gov ID: NCT05024162
What this study is testing
- What it's testing
- Prostate cancer is the most common cancer diagnosed in men in Canada. Magnetic resonance imaging (MRI) may become a valuable tool to non-invasively identify prostate cancer and assess its biological aggressiveness, which in turn will help doctors make better decisions about how to treat an individual patient's prostate cancer.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults, men only
You may be able to join if
- An appropriate diagnostic MRI-P, defined as:
- Being performed on 3T MRI at the Halifax Infirmary Building
- Taken place within 5 weeks of study enrolment
- Having a detectable nodule which anatomically localizes to prostate cancer (PCa) identified in diagnostic biopsy specimen
- Acquired T1+contrast, T2, and attenuated diffusion coefficient (ADC) series axial images of the prostate An appropriate diagnostic biopsy, defined as:
You likely can't join if
- Past prostatic interventions which would influence the prostate's structure
- Alterations to physiological testosterone levels
- Inability to position one's self in a reproducible fashion for an MRI-P
- Patient factors reported to produce significant artifact on MRI-P 1
See the full eligibility criteria
- An appropriate diagnostic MRI-P, defined as:
- Being performed on 3T MRI at the Halifax Infirmary Building
- Taken place within 5 weeks of study enrolment
- Having a detectable nodule which anatomically localizes to prostate cancer (PCa) identified in diagnostic biopsy specimen
- Acquired T1+contrast, T2, and attenuated diffusion coefficient (ADC) series axial images of the prostate An appropriate diagnostic biopsy, defined as:
- Taken place within 2 months of the participant's MRI-P 1
- Taken place within 3 months of participant's study enrolment
- Reports diagnosis of PCa
- Reports a systematic assessment of the biopsy, assessing at least 12 cores
- Reports at least on core involved with PCa and this core must anatomically localise to a nodule seen on MRI-P 1
- Past prostatic interventions which would influence the prostate's structure
- Alterations to physiological testosterone levels
- Inability to position one's self in a reproducible fashion for an MRI-P
- Patient factors reported to produce significant artifact on MRI-P 1
The study team makes the final eligibility decision.
Where it's taking place
- Halifax, Nova Scotia, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, not specified. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Halifax, Nova Scotia, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.